A phase III study examining the use of the phosphodiesterase type-5 inhibitor tadalafil in men with BPH is planned for 2006. The scheduled trial follows results of a double-blind, placebo-controlled phase II study showing clinically meaningful and statistically significant improvement in lower urinary tract symptoms in men with BPH who were treated for 6 weeks with once-daily tadalafil, 5 mg, according to Lilly ICOS LLC.
Whether you're interested in adding an associate to your practice or are seeking a move yourself, you're likely to en-counter physician recruiters. While working with a recruiter is not for every physician, it can save time and allow you to focus on what really matters: patient care.
Peripheral lesions are more amenable to ablation and are technically easier, but endophytic neoplasms can be performed with precise intraoperative imaging.
Amsterdam, Netherlands--Three-dimensional computed tomography reconstruction of the pelvicalyceal system helps in the planning and execution of percutaneous nephrolithotomy, but the relative value of each reconstruction method is not known.
Amsterdam, Netherlands--With U.S. experience with tubeless percutaneous nephrolithotomy (PNL) now reaching 9 years, several studies have demonstrated the procedure's safety and effectiveness. Stone-free rates are similar to that seen with standard PNL using nephrostomy tubes, but postoperative hospitalization and narcotic use are decreased with the tubeless procedure, according to study results presented at the World Congress on Endourology here.
Amsterdam, Netherlands--A protective polyamide laser sheath for use during flexible ureteroscopy and laser lithotripsy showed little effect on deflection characteristics but markedly impaired irrigation flow in a new study from Canada.
Paris--External irradiation immediately following radical prostatectomy appears to improve biochemical progression-free survival and local control in prostate cancer patients at high risk of progression, according to results of a study from the European Organization for Research and Treatment of Cancer (EORTC).
Paris--Results of a second phase III trial suggest that a still-investigational immunotherapy agent offers a survival benefit in men with asymptomatic metastatic androgen-independent prostate cancer. Survival data from the more recent study support the findings of the first phase III trial of the agent, APC8015, also known as sipuleucel-T (Provenge), researchers reported at the European Cancer Conference here.
New York--Differential diagnosis of erectile dysfunction doesn't appear worth the effort when selecting a drug for treatment: No meaningful difference in the effect of the three available phosphodiesterase type-5 inhibitors was seen among men in a clinical trial, regardless of the cause of their ED, according to Hartmut Porst, MD.
Amsterdam, Netherlands--Researchers performing removal of challenging renal tumors using laparoscopic partial nephrectomy (LPN) in 300 consecutive cases have found that, compared with the first 100 cases, blood loss and overall complications decreased despite increased complexity of treating surgically difficult small renal tumors.
Paris--Adding a form of high-dose calcitriol to docetaxel (Taxotere) offers improved survival over docetaxel alone in men with metastatic androgen-independent prostate cancer, according to results of a multicenter trial presented at the 13th European Cancer Conference (ECCO-13) here. Further, the addition of the calcitriol formulation, known as DN-101, to the chemotherapy agent produced an unanticipated advantage in a reduced number of serious gastrointestinal and thromboembolic adverse events.
Philadelphia--Enhancing renal masses are all presumed to be renal cell carcinoma until proven otherwise. While surgery remains the gold standard, those that are watched instead of excised carry a relatively low risk of metastasis. Unfortunately, size on presentation cannot tell clinicians about their true growth potential. Because not all enhancing renal masses are RCC, those that are, in fact, carcinomas grow faster than the masses left in place. Those are the conclusions of two different studies on the natural history of renal masses, one, a meta-analysis of the world literature and the other, an analysis of one center's experience.
Amsterdam, Netherlands--Participants in an AUA-sponsored laparoscopic videotape mentoring course, offered as part of a skills-based learning course, report an increase in their laparoscopic caseload and in the performance of clinical laparoscopic suturing.
Amsterdam, Netherlands--A model-based training format and an interactive virtual reality simulator trainer that were developed to teach basic ureteroscopy skills showed no significant points of difference when compared in use by inexperienced medical students, reported researchers from the University of California, Irvine.
Amsterdam, Netherlands--Open radical prostatectomy remains the standard surgical approach for the management of localized prostate adenocarcinoma, but recent data show that this may be changing. As robot-assisted surgery becomes more prevalent in the urologic community, practice patterns appear to be shifting from open radical prostatectomy toward robot-assisted laparoscopic radical prostatectomy.
Amsterdam, Netherlands--The extent to which American patients comprehend the technology behind robot-assisted radical prostatectomy is surprisingly limited, according to a prospective questionnaire evaluation from St. Peter's Hospital, Albany, NY.
Amsterdam, Netherlands--An increased body mass index has been shown to confound the outcome of numerous surgical treatments. The effect of BMI on cardiovascular disease, insulin resistance, cancer mortality, and blood loss during radical surgery is well documented. Less clear is the effect of BMI on laparoscopic surgery, including laparoscopic radical prostatectomy.
Amsterdam, Netherlands--Preoperative computed tomography scans may be inconclusive in distinguishing between stage pT2 and pT3a renal tumors. When performing laparoscopic partial nephrectomy, surgeons from the Cleveland Clinic recommend removing all peri-nephritic fat during the excision of locally advanced tumors, a step that they say is essential in duplicating open surgical oncologic principles.
Urology Times 2006 Rate Card
Urology Times 2006 Media Kit
A third interim safety analysis of an ongoing multicenter phase II trial of NX-1207, for the treatment of BPH, has revealed no serious side effects, according to Nymox Pharmaceutical Corp., the drug's manufacturer.
Former New York Knicks basketball star Earl "The Pearl" Monroe is the point man for the "Flomax One-Week Challenge," a national campaign to educate men about BPH.
The National Cancer Institute and the National Human Genome Research Institute have launched a comprehensive effort to accelerate the understanding of the molecular basis of cancer through genome analysis technologies, especially large-scale genome sequencing.
Researchers at the University of California, San Francisco have discovered that the activity of several embryonic stem cell genes is elevated in testicular cancer, providing some of the first molecular evidence of a link between embryonic stem cells and cancer.
A third interim safety analysis of an ongoing multicenter phase II trial of NX-1207, for the treatment of BPH, has revealed no serious side effects, according to Nymox Pharmaceutical Corp., the drug's manufacturer.
Urology Associates of Nashville, TN has opened a clinic dedicated to women's sexual health.
Measurement of telomerase activity in urine appears promising for the detection of bladder cancer in men, according to a study published last week in JAMA.
New Orleans--Hurricane Katrina has come and gone and in its wake we are left with devastation, carnage, and sadness. The region has more than 6,000 displaced physicians, and 156 AUA members have practices in the affected areas, according to AUA.
John J. Mulcahy, MD, PhD, has announced that he will be leaving Indiana University Medical Center and will move his practice to Phoenix, where he will be joining Urology Associates Ltd.
Mayo Clinic researchers say they have discovered that a molecule known as B7-H1 may serve as a "molecular armor," protecting kidney cancer by allowing it to grow and spread.